What are you searching for…

Monday October 7th the 2019 Nobel Prize in Physiology or Medicine 2019 was awarded jointly to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza "for their discoveries of how cells sense and adapt to oxygen availability."


William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza’s work has established the mechanisms that enables cells to quickly and precisely respond to changes in oxygen levels and thus revealed how one of life’s most essential adaptive processes work. These findings have implications for treating a variety of diseases, including cancer, anemia, cardiovascular disease and strokes but also have paved the way to understanding the basic biological phenomena.

To make breakthrough in science even the best scientists need tools to make history. For Sir Peter J. Ratcliffe this tool was provided by Andrew Skinn, a entrepreneur and innovator from the United Kingdom.

Andrew Skinn, founded Ruskinn Technology Ltd (now recognized as Baker Ruskinn) in 1998. Ruskinn developed the first low oxygen workstation – a complete novelty at the time – where cells could be cultured under their correct conditions (in vivo). This meant that it was now possible to see cellular events that had been missed before; even HIF-1 with its half-life of less than 5 minutes was now within the reach of brilliant minds to unravel.

In 1988, Andrew Skinn collaborated with Sir Peter J. Ratcliffe and his team with a vision to develop precision control oxygen technology with the launch of InvivO2. The InvivO2 workstation was designed and built to mimic the physiology of your subject matter, giving you the reassurance of precise results under controlled conditions. It allows you to study the most complex of cell interactions under precise physiological conditions, regulating and maintaining oxygen, carbon dioxide, temperature and humidity.

Since then Baker Ruskinn has been working with pioneering scientists around the world to make breakthroughs in cell research. Over those years, researchers have devoted their lives to advancing knowledge and understanding of the way cells behave, while knowing that Baker Ruskinn is the gold standard they can rely on.

Hundreds of leading scientists have trusted our brand to provide revolutionary technology in order to make their research possible, including William G. Kaelin and Sir Peter J. Ratcliffe whom are both long standing customers of Baker Ruskinn.

Baker Ruskinn are extremely proud to have been a part of the journey that has resulted in The Nobel Prize for William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza.

Baker Ruskinn are extremely proud to have been a part of the journey that has resulted in The Nobel Prize for William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza.


At Baker Ruskinn we believe that with remarkable minds and exceptional tools great things can be achieved. These kinds of breakthroughs are rarely made overnight and it can take years of hard work and dedication to be successful in experimental biology. But with such commitment to science we have witnessed in the achievements of these exceptional scientists, that it is possible – together with Baker Ruskinn.

Check out our research publications

Key publications


Maxwell, P.H., Wiesener, M.S., Chang, G.-W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R. & Ratcliffe, P.J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275

Mircea, I., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J.M., Lane, W.S. & Kaelin Jr., W.G. (2001) HIFa targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science, 292, 464-468

Jaakkola, P., Mole, D.R., Tian, Y.-M., Wilson, M.I., Gielbert, J., Gaskell, S.J., von Kriegsheim, A., Heberstreit, H.F., Mukherji, M., Schofield, C.J., Maxwell, P.H., Pugh, C.W. & Ratcliffe, P.J. (2001). Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292, 468-472

Stolze IP1, Tian YM, Appelhoff RJ, Turley H, Wykoff CC, Gleadle JM, Ratcliffe PJ. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes.J Biol Chem. 2004 Oct 8;279(41):42719-25.

Chakraborty AA, Laukka T, Myllykoski M, Ringel AE, Booker MA, Tolstorukov MY, Meng YJ, Meier SR, Jennings RB, Creech AL, Herbert ZT, McBrayer SK, Olenchock BA, Jaffe JD, Haigis MC, Beroukhim R, Signoretti S, Koivunen P, Kaelin WG Jr. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science. 2019 Mar 15;363(6432):1217-1222

Masson N, Keeley TP, Giuntoli B, White MD, Puerta ML, Perata P, Hopkinson RJ, Flashman E, Licausi F, Ratcliffe PJ. Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants. Science. 2019 Jul 5;365(6448):65-69.